Latest Insights - page 16 | BiopharmaTrend

How AI Powers Synthetic Biology

Let's face it, we are living in a "century of biology" and artificial intelligence is a growing enabler of what comes next. For billions of years, evolution was the only …

Continue ›››

From Gene Editing to Pathway Design: How AI is Transforming Synthetic Biology

Synthetic biology refers to the purposeful design and construction of new biological components, devices, and systems, as well as the re-engineering of existing natural biological systems to serve practical functions. …

Continue ›››

Iambic’s AI-Designed Cancer Drug Shows Early Clinical Activity

Iambic Therapeutics presented new data from its ongoing Phase 1/1b trial of IAM1363 at the 2025 ESMO Congress, showing anti-tumor activity in heavily pretreated patients with HER2-driven cancers, including those …

Continue ›››

Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape

Disclaimer: this post is not medical advice; the content of the post is for informational and educational purposes only. Over the past decade, aging research has transitioned from a mostly …

Continue ›››

7 Notable Companies Advancing Women’s Health with AI

Back in 2016, Ida Tin, the CEO behind the renowned period-tracking app Clue, introduced the term "FemTech" to capture the wave of startups pushing the boundaries of technology in the …

Continue ›››

AstraZeneca and AI-Powered Immune Mapping Company Immunai Sign Up To $85M IBD Target Agreement

Immunai has signed an agreement with AstraZeneca to develop a therapeutic target for inflammatory bowel disease (IBD), marking a shift from their existing oncology-focused collaboration started in 2022. The deal …

Continue ›››

Seven RNA Biotech Companies To Watch in 2026

For many years the focus of therapeutic developments and scientific research was directed at the genome and proteins. Yet, there is a completely different level of cell regulation – transcriptome …

Continue ›››

Takeda Expands AI-Driven Antibody Design Partnership with Nabla Bio in a Billion-Dollar Deal

U.S. biotech company Nabla Bio has signed a second major research partnership with Japan’s Takeda Pharmaceutical Co. (4502.T), expanding their collaboration in artificial intelligence-driven drug discovery. The new multi-year agreement …

Continue ›››

AI and CRISPR—converging revolutions in biomedicine?

Since the discovery of its mechanism in 2012, CRISPR-based gene editing has turned from basic discovery into a bioengineering tool now penetrating biomedicine and enabling breakthroughs in the treatment of …

Continue ›››

15 Useful Mobile Apps For Life Scientists

Nowadays, mobile devices are ubiquitous with an estimated number of smartphones and tablet PCs to exceed two billion globally. The availability of internet connection in most public places, powerful processors, …

Continue ›››

Inside Big Pharma's AI Playbook: From Molecule Discovery to Clinical Trials

7 fronts where Big Pharma explores AI via partnerships and internal programs. The traditional drug discovery process is among the most complex, costly, and time-consuming endeavors in science. Developing a …

Continue ›››

Five AI-driven Drug Discovery Companies Enabling Precision Oncology

Artificial Intelligence (AI) is steadily making its presence felt across various sectors, including the pharmaceutical industry. Among the multiple applications of AI in this field, immunotherapy—a treatment method that utilizes …

Continue ›››